Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy
Phase of Trial: Phase IV
Latest Information Update: 29 Dec 2018
At a glance
- Drugs Carfilzomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 17 Jun 2018 First planned interim analysis (as of 30 Oct 2017, n=85) results, presented at the 23rd Congress of the European Haematology Association.
- 24 May 2018 Planned number of patients changed from 1000 to 800.